Top

Acta Neuropathologica Communications

Published in:

Open Access 01-12-2014 | Research

Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain

Authors: Samira Saadoun, Patrick Waters, Gregory P Owens, Jeffrey L Bennett, Angela Vincent, Marios C Papadopoulos

Published in: Acta Neuropathologica Communications | Issue 1/2014

Abstract

Introduction

Antibodies against myelin oligodendrocyte glycoprotein (MOG-IgG) are present in some neuromyelitis optica patients who lack antibodies against aquaporin-4 (AQP4-IgG). The effects of neuromyelitis optica MOG-IgG in the central nervous system have not been investigated in vivo. We microinjected MOG-IgG, obtained from patients with neuromyelitis optica, into mouse brains and compared the results with AQP4-IgG.

Results

MOG-IgG caused myelin changes and altered the expression of axonal proteins that are essential for action potential firing, but did not produce inflammation, axonal loss, neuronal or astrocyte death. These changes were independent of complement and recovered within two weeks. By contrast, AQP4-IgG produced complement-mediated myelin loss, neuronal and astrocyte death with limited recovery at two weeks.

Conclusions

These differences mirror the better outcomes for MOG-IgG compared with AQP4-IgG patients and raise the possibility that MOG-IgG contributes to pathology in some neuromyelitis optica patients.

Available only for authorised users

Waters PJ, McKeon A, Leite MI, Rajasekharan S, Lennon VA, Villalobos A, Palace J, Mandrekar JN, Vincent A, Bar-Or A, Pittock SJ: Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology 2012, 78(9):665–671. discussion 669. doi:10.1212/WNL.0b013e318248dec1 10.1212/WNL.0b013e318248dec1CrossRefPubMedPubMedCentral

Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR: IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005, 202(4):473–477. doi:10.1084/jem.20050304 10.1084/jem.20050304CrossRefPubMedPubMedCentral

Papadopoulos MC, Verkman AS: Aquaporin water channels in the nervous system. Nat Rev Neurosci 2013, 14(4):265–277. doi:10.1038/nrn3468 10.1038/nrn3468CrossRefPubMedPubMedCentral

Hinson SR, Pittock SJ, Lucchinetti CF, Roemer SF, Fryer JP, Kryzer TJ, Lennon VA: Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology 2007, 69(24):2221–2231. doi:10.1212/01.WNL.0000289761.64862.ce 10.1212/01.WNL.0000289761.64862.ceCrossRefPubMed

Saadoun S, Waters P, Bell BA, Vincent A, Verkman AS, Papadopoulos MC: Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain 2010, 133(Pt 2):349–361.CrossRefPubMedPubMedCentral

Papadopoulos MC, Verkman AS: Aquaporin 4 and neuromyelitis optica. Lancet Neurol 2012, 11(6):535–544. doi:10.1016/S1474–4422(12)70133–3 10.1016/S1474-4422(12)70133-3CrossRefPubMedPubMedCentral

Matiello M, Lennon VA, Jacob A, Pittock SJ, Lucchinetti CF, Wingerchuk DM, Weinshenker BG: NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology 2008, 70(23):2197–2200. 10.1212/01.wnl.0000303817.82134.daCrossRefPubMed

Jarius S, Ruprecht K, Wildemann B, Kuempfel T, Ringelstein M, Geis C, Kleiter I, Kleinschnitz C, Berthele A, Brettschneider J, Hellwig K, Hemmer B, Linker RA, Lauda F, Mayer CA, Tumani H, Melms A, Trebst C, Stangel M, Marziniak M, Hoffmann F, Schippling S, Faiss JH, Neuhaus O, Ettrich B, Zentner C, Guthke K, Hofstadt-van Oy U, Reuss R, Pellkofer H, et al.: Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation 2012, 9(1):14. doi:10.1186/1742–2094–9-14 10.1186/1742-2094-9-14CrossRefPubMedPubMedCentral

Akman-Demir G, Tuzun E, Waters P, Icoz S, Kurtuncu M, Jarius S, Yapici Z, Mutlu M, Yesilot N, Vincent A, Eraksoy M: Prognostic implications of aquaporin-4 antibody status in neuromyelitis optica patients. J Neurol 2011, 258(3):464–470. doi:10.1007/s00415–010–5780–4 10.1007/s00415-010-5780-4CrossRefPubMed

10.

Kitley J, Leite MI, Kuker W, Quaghebeur G, George J, Waters P, Woodhall M, Vincent A, Palace J: Longitudinally extensive transverse myelitis with and without aquaporin 4 antibodies. JAMA Neurol 2013. EPub ahead of print. doi:10.1001/jamaneurol.2013.3890

11.

Kitley J, Woodhall M, Waters P, Leite MI, Devenney E, Craig J, Palace J, Vincent A: Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology 2012, 79(12):1273–1277. doi:10.1212/WNL.0b013e31826aac4e 10.1212/WNL.0b013e31826aac4eCrossRefPubMed

12.

Mader S, Gredler V, Schanda K, Rostasy K, Dujmovic I, Pfaller K, Lutterotti A, Jarius S, Di Pauli F, Kuenz B, Ehling R, Hegen H, Deisenhammer F, Aboul-Enein F, Storch MK, Koson P, Drulovic J, Kristoferitsch W, Berger T, Reindl M: Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflammation 2011, 8: 184. doi:10.1186/1742–2094–8-184 10.1186/1742-2094-8-184CrossRefPubMedPubMedCentral

13.

Rostasy K, Mader S, Hennes EM, Schanda K, Gredler V, Guenther A, Blaschek A, Korenke C, Pritsch M, Pohl D, Maier O, Kuchukhidze G, Brunner-Krainz M, Berger T, Reindl M: Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica. Mult Scler 2013, 19(8):1052–1059. doi:10.1177/1352458512470310 10.1177/1352458512470310CrossRefPubMed

14.

Vourc’h P, Andres C: Oligodendrocyte myelin glycoprotein (OMgp): evolution, structure and function. Brain Res Brain Res Rev 2004, 45(2):115–124. doi:10.1016/j.brainresrev.2004.01.003 10.1016/j.brainresrev.2004.01.003CrossRefPubMed

15.

Kitley J, Waters P, Woodhall M, Leite MI, Murchison A, George J, Kuker W, Chandratre S, Vincent A, Palace J: Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol 2014. doi:10.1001/jamaneurol.2013.5857

16.

Sato DK, Callegaro D, Lana-Peixoto MA, Waters PJ, de Haidar Jorge FM, Takahashi T, Nakashima I, Apostolos-Pereira SL, Talim N, Simm RF, Martins Lino AM, Misu T, Leite MI, Aoki M, Fujihara K: Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 2014. doi:10.1212/WNL.0000000000000101

17.

Saadoun S, Waters P, MacDonald C, Bell BA, Vincent A, Verkman AS, Papadopoulos MC: Neutrophil protease inhibition reduces NMO-IgG-induced damage in mouse brain. Ann Neurol 2012, 71(3):323–333. doi:10.1002/ana.22686 10.1002/ana.22686CrossRefPubMedPubMedCentral

18.

Saadoun S, Waters P, Macdonald C, Bridges LR, Bell BA, Vincent A, Verkman AS, Papadopoulos MC: T cell deficiency does not reduce lesions in mice produced by intracerebral injection of NMO-IgG and complement. J Neuroimmunol 2011, 235(1–2):27–32. doi:10.1016/j.jneuroim.2011.03.007CrossRefPubMed

19.

Owens GP, Bennett JL, Lassmann H, O’Connor KC, Ritchie AM, Shearer A, Lam C, Yu X, Birlea M, DuPree C, Williamson RA, Hafler DA, Burgoon MP, Gilden D: Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid. Ann Neurol 2009, 65(6):639–649. doi:10.1002/ana.21641 10.1002/ana.21641CrossRefPubMedPubMedCentral

20.

Bennett JL, Lam C, Kalluri SR, Saikali P, Bautista K, Dupree C, Glogowska M, Case D, Antel JP, Owens GP, Gilden D, Nessler S, Stadelmann C, Hemmer B: Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol 2009, 66(5):617–629. doi: 10.1002/ana.21802 10.1002/ana.21802CrossRefPubMedPubMedCentral

21.

Zhou D, Lambert S, Malen PL, Carpenter S, Boland LM, Bennett V: AnkyrinG is required for clustering of voltage-gated Na channels at axon initial segments and for normal action potential firing. J Cell Biol 1998, 143(5):1295–1304. 10.1083/jcb.143.5.1295CrossRefPubMedPubMedCentral

22.

Bhat MA, Rios JC, Lu Y, Garcia-Fresco GP, Ching W, St Martin M, Li J, Einheber S, Chesler M, Rosenbluth J, Salzer JL, Bellen HJ: Axon-glia interactions and the domain organization of myelinated axons requires neurexin IV/Caspr/Paranodin. Neuron 2001, 30(2):369–383. 10.1016/S0896-6273(01)00294-XCrossRefPubMed

23.

Mayer MC, Breithaupt C, Reindl M, Schanda K, Rostasy K, Berger T, Dale RC, Brilot F, Olsson T, Jenne D, Probstel AK, Dornmair K, Wekerle H, Hohlfeld R, Banwell B, Bar-Or A, Meinl E: Distinction and temporal stability of conformational epitopes on myelin oligodendrocyte glycoprotein recognized by patients with different inflammatory central nervous system diseases. J Immunol 2013, 191(7):3594–3604. doi:10.4049/jimmunol.1301296 10.4049/jimmunol.1301296CrossRefPubMed

24.

Marta CB, Oliver AR, Sweet RA, Pfeiffer SE, Ruddle NH: Pathogenic myelin oligodendrocyte glycoprotein antibodies recognize glycosylated epitopes and perturb oligodendrocyte physiology. Proc Natl Acad Sci U S A 2005, 102(39):13992–13997. doi:10.1073/pnas.0504979102 10.1073/pnas.0504979102CrossRefPubMedPubMedCentral

25.

Marta CB, Taylor CM, Coetzee T, Kim T, Winkler S, Bansal R, Pfeiffer SE: Antibody cross-linking of myelin oligodendrocyte glycoprotein leads to its rapid repartitioning into detergent-insoluble fractions, and altered protein phosphorylation and cell morphology. J Neurosci 2003, 23(13):5461–5471.PubMed

26.

Lee DH, Linker RA: The role of myelin oligodendrocyte glycoprotein in autoimmune demyelination: a target for multiple sclerosis therapy? Expert Opin Ther Targets 2012, 16(5):451–462. doi: 10.1517/14728222.2012.677438 10.1517/14728222.2012.677438CrossRefPubMed

27.

Zhou D, Srivastava R, Nessler S, Grummel V, Sommer N, Bruck W, Hartung HP, Stadelmann C, Hemmer B: Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. Proc Natl Acad Sci U S A 2006, 103(50):19057–19062. doi:10.1073/pnas.0607242103 10.1073/pnas.0607242103CrossRefPubMedPubMedCentral

28.

Chernoff GF: Shiverer: an autosomal recessive mutant mouse with myelin deficiency. J Hered 1981, 72(2):128.PubMed

29.

Reindl M, Di Pauli F, Rostasy K, Berger T: The spectrum of MOG autoantibody-associated demyelinating diseases. Nat Rev Neurol 2013, 9(8):455–461. doi: 10.1038/nrneurol.2013.118 10.1038/nrneurol.2013.118CrossRefPubMed

30.

Pittock SJ, Lennon VA, McKeon A, Mandrekar J, Weinshenker BG, Lucchinetti CF, O’Toole O, Wingerchuk DM: Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol 2013, 12(6):554–562. doi:10.1016/S1474–4422(13)70076–0 10.1016/S1474-4422(13)70076-0CrossRefPubMed

Title: Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain
Authors: Samira Saadoun
Patrick Waters
Gregory P Owens
Jeffrey L Bennett
Angela Vincent
Marios C Papadopoulos
Publication date: 01-12-2014
Publisher: BioMed Central
Published in: Acta Neuropathologica Communications / Issue 1/2014
Electronic ISSN: 2051-5960
DOI: https://doi.org/10.1186/2051-5960-2-35

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain

Abstract

Introduction

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2014

Polycomb group gene BMI1 controls invasion of medulloblastoma cells and inhibits BMP-regulated cell adhesion

MotorPlex provides accurate variant detection across large muscle genes both in single myopathic patients and in pools of DNA samples

Increased 5-hydroxymethylcytosine and decreased 5-methylcytosine are indicators of global epigenetic dysregulation in diffuse intrinsic pontine glioma

D-2-Hydroxyglutarate producing neo-enzymatic activity inversely correlates with frequency of the type of isocitrate dehydrogenase 1 mutations found in glioma

Metabolic alterations due to IDH1 mutation in glioma: opening for therapeutic opportunities?

MARK4 and MARK3 associate with early tau phosphorylation in Alzheimer’s disease granulovacuolar degeneration bodies